Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-ARM randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861)
1990 ◽
Vol 37
(6)
◽
pp. 1013-1019
◽
2006 ◽
Vol 17
(10)
◽
pp. 1201-1209
◽